Literature DB >> 24574080

Monitoring drug markets in the Internet age and the evolution of drug monitoring systems in Australia.

Lucy Burns1, Amanda Roxburgh, Raimondo Bruno, Joe Van Buskirk.   

Abstract

In Australia, drug monitoring systems have been in place for more than a decade allowing for the measurement of ongoing trends in drug use and the detection of new drugs. The Drug Trends Unit at the National Drug and Alcohol Research Centre monitors drugs through four separate systems. The Illicit Drug Reporting System (IDRS) measures the price, purity, and availability of drugs that are primarily injected. The Ecstasy and Related Drugs Reporting System (EDRS) monitors psychostimulants that are used recreationally. The National Illicit Drugs Indicator Project (NIDIP) analyzes indicator data including drug-related hospitalizations and deaths. Finally, the Drugs and Emerging Technologies Project (DNeT) analyzes the role of the Internet in the procurement and use of novel psychoactive substances. This paper provides an overview of each component of the system, demonstrating how the system has evolved over time.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Internet; ecstasy; new psychoactive substances

Mesh:

Substances:

Year:  2014        PMID: 24574080     DOI: 10.1002/dta.1613

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  8 in total

1.  Global trends, local harms: availability of fentanyl-type drugs on the dark web and accidental overdoses in Ohio.

Authors:  Usha Lokala; Francois R Lamy; Raminta Daniulaityte; Amit Sheth; Ramzi W Nahhas; Jason I Roden; Shweta Yadav; Robert G Carlson
Journal:  Comput Math Organ Theory       Date:  2018-10-25       Impact factor: 2.023

Review 2.  Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants.

Authors:  Cristina Miliano; Giovanni Serpelloni; Claudia Rimondo; Maddalena Mereu; Matteo Marti; Maria Antonietta De Luca
Journal:  Front Neurosci       Date:  2016-04-19       Impact factor: 4.677

3.  Using Social Listening Data to Monitor Misuse and Nonmedical Use of Bupropion: A Content Analysis.

Authors:  Laurie S Anderson; Heidi G Bell; Michael Gilbert; Julie E Davidson; Christina Winter; Monica J Barratt; Beta Win; Jeffery L Painter; Christopher Menone; Jonathan Sayegh; Nabarun Dasgupta
Journal:  JMIR Public Health Surveill       Date:  2017-02-01

4.  Opioid use and harms associated with a sustained-release tapentadol formulation: a postmarketing study protocol.

Authors:  Amy Peacock; Briony Larance; Michael Farrell; Rose Cairns; Nicholas Buckley; Louisa Degenhardt
Journal:  BMJ Open       Date:  2018-03-23       Impact factor: 2.692

Review 5.  Sales and Advertising Channels of New Psychoactive Substances (NPS): Internet, Social Networks, and Smartphone Apps.

Authors:  Cristina Miliano; Giulia Margiani; Liana Fattore; Maria Antonietta De Luca
Journal:  Brain Sci       Date:  2018-06-29

6.  "When they say weed causes depression, but it's your fav antidepressant": Knowledge-aware attention framework for relationship extraction.

Authors:  Shweta Yadav; Usha Lokala; Raminta Daniulaityte; Krishnaprasad Thirunarayan; Francois Lamy; Amit Sheth
Journal:  PLoS One       Date:  2021-03-25       Impact factor: 3.240

7.  'Worth the test?' Pragmatism, pill testing and drug policy in Australia.

Authors:  Andrew Groves
Journal:  Harm Reduct J       Date:  2018-04-10

8.  Changes in illicit drug use and markets with the COVID-19 pandemic and associated restrictions: findings from the Ecstasy and Related Drugs Reporting System, 2016-20.

Authors:  Olivia Price; Nicola Man; Raimondo Bruno; Paul Dietze; Caroline Salom; Simon Lenton; Jodie Grigg; Daisy Gibbs; Tanya Wilson; Louisa Degenhardt; Roanna Chan; Natalie Thomas; Amy Peacock
Journal:  Addiction       Date:  2021-07-16       Impact factor: 7.256

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.